Kaiyuan Yang1,2,3, Xiaohui Ren1,2,3, Liyuan Tao4, Peipei Wang5,6, Haihui Jiang1,2,3, Li Shen5,6, Yiming Zhao4, Yong Cui1,2,3, Mingxiao Li1,2,3, Song Lin1,2,3. 1. Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China. 2. China National Clinical Research Center for Neurological Diseases, Beijing 100070, China. 3. Beijing Neurosurgical Institution, Capital Medical University, Beijing 100050, China. 4. Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing 100191, China. 5. Department of Cell Biology, Peking University Health Science Center, Beijing 100191, China. 6. Peking University Stem Cell Research Center, Beijing 100191, China.
Abstract
OBJECTIVE: To determine the prognostic implications and clinical significance of epidermal growth factor receptor variant III (EGFRvIII) expression and EGFRvIII nuclear translocation in Chinese human gliomas. METHODS: We retrospectively examined EGFRvIII expression and EGFRvIII nuclear translocation using immunohistochemistry in specimens of 240 Chinese patients with glioma, including 84 World Health Organization (WHO) II gliomas, 84 WHO III gliomas and 72 glioblastomas (WHO IV). Factors that correlated with EGFRvIII and EGFRvIII nuclear translocation expression were analyzed by the Chi-square test. Kaplan-Meier methodology and Cox regression were used for the survival analysis. RESULTS: Log-rank tests showed that patient age, Karnofsky performance scale (KPS) score, tumor grade, EGFRvIII expression, EGFRvIII nuclear translocation, 1p/19q codeletion, isocitrate dehydrogenase (IDH) mutation, Ki-67 labeling index and O6-methylguanine-DNA methyltransferase (MGMT) status (P<0.05) were significantly correlated with overall survival (OS) time. Multivariate Cox regression analysis revealed that patient age, tumor grade, EGFRvIII nuclear translocation, 1p/19q codeletion, and IDH mutation (P<0.05) were significantly correlated with OS. Patients with a high level of EGFRvIII nuclear translocation (≥7%) had both significantly shorter OS [hazard ratio (HR): 1.920, 95% confidence interval (95% CI): 1.228-3.003, P=0.004] and progression-free survival (PFS) times (HR: 1.661, 95% CI: 1.116-2.471, P=0.012) than those with a low level of EGFRvIII nuclear translocation (<7%). CONCLUSIONS: A high level of EGFRvIII nuclear translocation in glioma is an independent factor indicating a poor prognosis, but EGFRvIII expression is not an independent clinical prognostic factor. The level of EGFRvIII nuclear translocation maybe a novel and crucial prognostic biomarker in glioma.
OBJECTIVE: To determine the prognostic implications and clinical significance of epidermal growth factor receptor variant III (EGFRvIII) expression and EGFRvIII nuclear translocation in Chinese human gliomas. METHODS: We retrospectively examined EGFRvIII expression and EGFRvIII nuclear translocation using immunohistochemistry in specimens of 240 Chinese patients with glioma, including 84 World Health Organization (WHO) II gliomas, 84 WHO III gliomas and 72 glioblastomas (WHO IV). Factors that correlated with EGFRvIII and EGFRvIII nuclear translocation expression were analyzed by the Chi-square test. Kaplan-Meier methodology and Cox regression were used for the survival analysis. RESULTS: Log-rank tests showed that patient age, Karnofsky performance scale (KPS) score, tumor grade, EGFRvIII expression, EGFRvIII nuclear translocation, 1p/19q codeletion, isocitrate dehydrogenase (IDH) mutation, Ki-67 labeling index and O6-methylguanine-DNA methyltransferase (MGMT) status (P<0.05) were significantly correlated with overall survival (OS) time. Multivariate Cox regression analysis revealed that patient age, tumor grade, EGFRvIII nuclear translocation, 1p/19q codeletion, and IDH mutation (P<0.05) were significantly correlated with OS. Patients with a high level of EGFRvIII nuclear translocation (≥7%) had both significantly shorter OS [hazard ratio (HR): 1.920, 95% confidence interval (95% CI): 1.228-3.003, P=0.004] and progression-free survival (PFS) times (HR: 1.661, 95% CI: 1.116-2.471, P=0.012) than those with a low level of EGFRvIII nuclear translocation (<7%). CONCLUSIONS: A high level of EGFRvIII nuclear translocation in glioma is an independent factor indicating a poor prognosis, but EGFRvIII expression is not an independent clinical prognostic factor. The level of EGFRvIII nuclear translocation maybe a novel and crucial prognostic biomarker in glioma.
Authors: Joanne Edwards; Pamela Traynor; Alison F Munro; Catherine F Pirret; Barbara Dunne; John M S Bartlett Journal: Clin Cancer Res Date: 2006-01-01 Impact factor: 12.531
Authors: Daphne A Haas-Kogan; Michael D Prados; Tarik Tihan; David A Eberhard; Nannette Jelluma; Nils D Arvold; Rachel Baumber; Kathleen R Lamborn; Ami Kapadia; Mary Malec; Mitchel S Berger; David Stokoe Journal: J Natl Cancer Inst Date: 2005-06-15 Impact factor: 13.506
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Marta Viana-Pereira; José Manuel Lopes; Suzie Little; Fernanda Milanezi; Diana Basto; Fernando Pardal; Chris Jones; Rui Manuel Reis Journal: Anticancer Res Date: 2008 Mar-Apr Impact factor: 2.480
Authors: Dirk Vordermark; Klemens Ruprecht; Peter Rieckmann; Wolfgang Roggendorf; Giles H Vince; Monika Warmuth-Metz; Oliver Kölbl; Michael Flentje Journal: BMC Cancer Date: 2006-10-18 Impact factor: 4.430
Authors: David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues Journal: Acta Neuropathol Date: 2007-07-06 Impact factor: 17.088